BioSpace News Archive

Anocca AB announces that the company has successfully raised SEK 400 million through an equity financing round led by AMF and Mellby Gård.

AbbVie announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active systemic lupus erythematosus who continued to receive standard lupus therapies.

SNIPR Biome ApS announces positive interim clinical results from its Phase 1 clinical trial with SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.

BiomX Inc. announced that the Company will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during the Late-Breaking Science Session at 46th European Cystic Fibrosis Conference, which is being held June 7-10th, 2023, in Vienna, Austria.

Asieris Pharmaceuticals announced the phase I clinical data of ANTICIPATE Study was published for the first time at the 2023 American Society of Clinical Oncology annual meeting in Chicago.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).

Invitae, a leading medical genetics company, announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 12:40 p.m. Central Time.

Silence Therapeutics plc today announced that the Company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:00 – 4:25 PM EDT.

Algernon Pharmaceuticals Inc. is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office (JPO) for patent application 2021-522114 entitled “Compositions and Methods for Treating Chronic Kidney Disease” for its lead chronic kidney disease (CKD) program drug NP-251.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.